Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Hoofddorp – page 13

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hoofddorp at a glance
1 940
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 940 trials in Hoofddorp

Open in trial search

Alpha-1 antitrypsin deficiency

Recruiting

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:RNACS24757
  • Sponsor:Tessera Therapeutics Inc.

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Glycogen storage disease type II

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:DNL952
  • Sponsor:Denali Therapeutics Inc.

Factor VIII deficiency

Recruiting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Factor VIII deficiency

Recruiting

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Post-acute COVID-19 syndrome

Recruiting

Study of Fludeoxyglucose (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Amsterdam UMC Stichting

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Transitional cell carcinoma metastatic

Recruiting

Safety and Antitumor Activity of PF-08634404 Alone or with Enfortumab Vedotin in Adults with Locally Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Duchenne muscular dystrophy

Recruiting

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Neoplasm

Recruiting

Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage III

Recruiting

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatments
  • Urothelial Cancer Therapies
  • Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

  • B-Cell Lymphoma Treatments
  • Myelofibrosis Therapies
  • Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

  • Weight Management Interventions
  • Surgical Techniques
  • Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.